As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab||590||Esophageal Neoplasms||Phase 3||Recruiting|
|Study of Pembrolizumab in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction||180||
||Phase 2||Active, not recruiting|
|Study of Pembrolizumab Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy||181||
||Phase 3||Active, not recruiting|